343 related articles for article (PubMed ID: 30129889)
21. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
22. Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients.
Aldawish M; Jha N; McEwan AJ; Severin D; Ghosh S; Morrish DW
Endocr Res; 2014; 39(4):157-63. PubMed ID: 24460082
[TBL] [Abstract][Full Text] [Related]
23. Dynamic risk stratification in papillary thyroid carcinoma measuring 1 to 4 cm.
Lee YM; Cho JW; Hong SJ; Yoon JH
J Surg Oncol; 2018 Sep; 118(4):636-643. PubMed ID: 30114339
[TBL] [Abstract][Full Text] [Related]
24. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients.
Castagna MG; Maino F; Cipri C; Belardini V; Theodoropoulou A; Cevenini G; Pacini F
Eur J Endocrinol; 2011 Sep; 165(3):441-6. PubMed ID: 21750043
[TBL] [Abstract][Full Text] [Related]
25. Surgery for Neck Recurrence of Differentiated Thyroid Cancer: Outcomes and Risk Factors.
Lamartina L; Borget I; Mirghani H; Al Ghuzlan A; Berdelou A; Bidault F; Deandreis D; Baudin E; Travagli JP; Schlumberger M; Hartl DM; Leboulleux S
J Clin Endocrinol Metab; 2017 Mar; 102(3):1020-1031. PubMed ID: 28359102
[TBL] [Abstract][Full Text] [Related]
26. Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma.
Jeon MJ; Kim WG; Park WR; Han JM; Kim TY; Song DE; Chung KW; Ryu JS; Hong SJ; Shong YK; Kim WB
Eur J Endocrinol; 2014 Jan; 170(1):23-30. PubMed ID: 24088549
[TBL] [Abstract][Full Text] [Related]
27. Patients with Papillary Thyroid Carcinoma at Intermediate Risk of Recurrence According to American Thyroid Association Criteria Can Be Reclassified as Low Risk When the Postoperative Thyroglobulin Is Low.
Rosario PW; Furtado Mde S; Mourão GF; Calsolari MR
Thyroid; 2015 Nov; 25(11):1243-8. PubMed ID: 26359309
[TBL] [Abstract][Full Text] [Related]
28. Distant Metastasis in Pediatric and Adolescent Differentiated Thyroid Cancer: Clinical Outcomes and Risk Factor Analyses.
Sugino K; Nagahama M; Kitagawa W; Ohkuwa K; Uruno T; Matsuzu K; Suzuki A; Tomoda C; Hames KY; Akaishi J; Masaki C; Ito K
J Clin Endocrinol Metab; 2020 Nov; 105(11):. PubMed ID: 32813019
[TBL] [Abstract][Full Text] [Related]
29. Validation of dynamic risk stratification in pediatric differentiated thyroid cancer.
Sohn SY; Kim YN; Kim HI; Kim TH; Kim SW; Chung JH
Endocrine; 2017 Oct; 58(1):167-175. PubMed ID: 28822062
[TBL] [Abstract][Full Text] [Related]
30. Dynamic Risk Estimates of Outcome in Chinese Patients with Well-Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation.
Shen FC; Hsieh CJ; Huang IC; Chang YH; Wang PW
Thyroid; 2017 Apr; 27(4):531-536. PubMed ID: 28007013
[TBL] [Abstract][Full Text] [Related]
31. Practical Performance of the 2015 American Thyroid Association Guidelines for Predicting Tumor Recurrence in Patients with Papillary Thyroid Cancer in South Korea.
Lee SG; Lee WK; Lee HS; Moon J; Lee CR; Kang SW; Jeong JJ; Nam KH; Chung WY; Jo YS; Lee J
Thyroid; 2017 Feb; 27(2):174-181. PubMed ID: 27750028
[TBL] [Abstract][Full Text] [Related]
32. An Increased Neutrophil-to-Lymphocyte Ratio Predicts Incomplete Response to Therapy in Differentiated Thyroid Cancer.
Lee F; Yang PS; Chien MN; Lee JJ; Leung CH; Cheng SP
Int J Med Sci; 2018; 15(14):1757-1763. PubMed ID: 30588200
[No Abstract] [Full Text] [Related]
33. Low Recurrence Rates in a Cohort of Differentiated Thyroid Carcinoma Patients: A Referral Center Experience.
Scheffel RS; Zanella AB; Antunes D; Dora JM; Maia AL
Thyroid; 2015 Aug; 25(8):883-9. PubMed ID: 26061907
[TBL] [Abstract][Full Text] [Related]
34. Long-term follow-up of differentiated thyroid carcinoma in children and adolescents.
Negre Busó M; García Burillo A; Simó Perdigó M; Galofré Mora P; Boronat de Ferrater M; Cuberas Borrós G; Sábado Álvarez C; Castell Conesa J
J Pediatr Endocrinol Metab; 2020 Nov; 33(11):1431-1441. PubMed ID: 32877364
[TBL] [Abstract][Full Text] [Related]
35. Practical Initial Risk Stratification Based on Lymph Node Metastases in Pediatric and Adolescent Differentiated Thyroid Cancer.
Jeon MJ; Kim YN; Sung TY; Hong SJ; Cho YY; Kim TY; Shong YK; Kim WB; Kim SW; Chung JH; Kim TH; Kim WG
Thyroid; 2018 Feb; 28(2):193-200. PubMed ID: 29179646
[TBL] [Abstract][Full Text] [Related]
36. Long-term outcome of differentiated thyroid cancer in children and young adults: risk stratification by ATA criteria and assessment of pre-ablation stimulated thyroglobulin as predictors of disease persistence.
Karapanou O; Tzanela M; Rondogianni P; Dacou-Voutetakis C; Chiotis D; Vlassopoulou B; Vassiliadi D; Kanaka-Gantenbein C; Tsagarakis S
Endocrine; 2020 Dec; 70(3):566-574. PubMed ID: 32533509
[TBL] [Abstract][Full Text] [Related]
37. Dynamic risk stratification for medullary thyroid cancer according to the response to initial therapy.
Kwon H; Kim WG; Jeon MJ; Song DE; Lee YM; Sung TY; Chung KW; Yoon JH; Hong SJ; Baek JH; Lee JH; Kim TY; Kim WB; Shong YK
Endocrine; 2016 Jul; 53(1):174-81. PubMed ID: 26754662
[TBL] [Abstract][Full Text] [Related]
38. Refining Dynamic Risk Stratification and Prognostic Groups for Differentiated Thyroid Cancer With TERT Promoter Mutations.
Kim TH; Ki CS; Kim HS; Kim K; Choe JH; Kim JH; Kim JS; Oh YL; Hahn SY; Shin JH; Jang HW; Kim SW; Chung JH
J Clin Endocrinol Metab; 2017 May; 102(5):1757-1764. PubMed ID: 28323925
[TBL] [Abstract][Full Text] [Related]
39. The Prospective Implementation of the 2015 ATA Guidelines and Modified ATA Recurrence Risk Stratification System for Treatment of Differentiated Thyroid Cancer in a Canadian Tertiary Care Referral Setting.
Wu J; Hu XY; Ghaznavi S; Kinnear S; Symonds CJ; Grundy P; Parkins VM; Sharma P; Lamb D; Khalil M; Hyrcza M; Chandarana SP; Pasieka JL; Harvey A; Warshawski J; Hart R; Deutschman M; Randall DR; Paschke R
Thyroid; 2022 Dec; 32(12):1509-1518. PubMed ID: 36226405
[No Abstract] [Full Text] [Related]
40. Timing of Radioactive Iodine Administration Does Not Influence Outcomes in Patients with Differentiated Thyroid Carcinoma.
Scheffel RS; Zanella AB; Dora JM; Maia AL
Thyroid; 2016 Nov; 26(11):1623-1629. PubMed ID: 27549175
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
